The Gastrointestinal Dysfunction Scale for Parkinson's Disease.
Marta Camacho, Julia C Greenland, Caroline H Williams-Gray
https://pubmed.ncbi.nlm.nih.gov/34133059/Actively Recruiting
Led by University of Cambridge · Updated on 2026-08-25
215
Participants Needed
1
Research Sites
39 weeks
Total Duration
Researchers are investigating the role of methane-producing microbes in the gut and their link to Parkinsons disease PD and related neurological conditions like dementia and mild cognitive impairment. The study aims to understand how intestinal methanogen overgrowth IMO, detected by breath methane levels, is associated with gut symptoms, motor and cognitive problems, and disease progression. This includes exploring inflammation and gut-brain interactions among people with PD, high risk of PD, cognitive impairment, and healthy controls. The study has two parts an observational study following 200 participants from four groups over 18 months with two visits, assessing breath methane, stool microbiology, blood inflammation markers, and neurological and cognitive tests. A smaller experimental study will involve 15 participants with PD and high methane levels taking a daily probiotic supplement Limosilactobacillus reuteri for 18 months to evaluate its effect on methane production, gut microbes, inflammation, and clinical symptoms. Participants will undergo breath tests, stool and blood sample collection, and clinical assessments including neurological exams and questionnaires at baseline and after 18 months. The study will measure changes in breath methane, gut microbes, inflammation, motor and cognitive function, and disease progression. The probiotic groups outcomes will include methane levels and inflammatory markers. The total participation time is about 18 months, with close monitoring of symptoms and biological markers to explore methanes potential as a biomarker and therapeutic target.
CONDITIONS
The Role of METhanogens in the PROgression Of Parkinson's Disease and Related Neurological Conditions
M
Marta Camacho, Dr.
C
Caroline Williams-Gray, Dr.
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
University of Cambridge
Lead Sponsor
Parkinson's UK
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 screening visit
Duration - 18 months
Participants attend two visits 18 months apart for breath methane testing, stool and blood sample collection, and clinical and cognitive assessments to monitor gut microbes, inflammation, and neurological symptoms.
2 visits (baseline and 18 months)
Duration - 18 months
Participants with high methane levels take a daily probiotic capsule for 18 months while undergoing regular testing to evaluate effects on methane production, gut microbes, inflammation, and symptoms.
Regular visits during intervention
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SEQUENTIAL
Primary Purpose
OTHER
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Marta Camacho, Julia C Greenland, Caroline H Williams-Gray
https://pubmed.ncbi.nlm.nih.gov/34133059/M Camacho, A D Macleod, J Maple-Grødem...
https://pubmed.ncbi.nlm.nih.gov/34039994/V Ojetti, C Petruzziello, A Migneco...
https://pubmed.ncbi.nlm.nih.gov/28429333/University of Cambridge
Lead Sponsor
Parkinson's UK
Collaborating Sponsor